文献速递炎症性肠病

炎症性肠病社会成本系统综述:生物制剂推动费用上升且存在地域差异

Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
PubMed 文献 · Aliment Pharmacol Ther · 2021-06-11

该系统综述纳入Embase、Medline、Web of Science和Google Scholar中基于人群的炎症性肠病成本研究,将费用调整为2018年美元。结果显示克罗恩病和溃疡性结肠炎的年医疗费用以北美最高、亚洲最低,主要驱动因素为药物费用,1985至2018年间显著上升,而门诊和住院费用保持稳定。生物制剂虽预期减少住院和手术,但相关费用并未下降。

要点

  • 药物是主要成本驱动因素,1985至2018年药物费用显著上升,门诊和住院费用稳定。

核心结论

  • 炎症性肠病的社会成本正在上升,主要由药物费用增长驱动,且各大洲之间差异很大。

研究设计与样本

  • 系统综述纳入Embase、Medline、Web of Science和Google Scholar中所有基于人群的炎症性肠病成本研究,费用调整为2018年美元。

主要发现

  • 药物是主要成本驱动因素,其费用在1985至2018年间显著上升,而门诊和住院费用保持稳定。
  • 炎症性肠病对工作生产力有负面影响,克罗恩病和溃疡性结肠炎的年缺勤成本各洲不同。

关键数值与推荐

  • 克罗恩病年缺勤成本(含假性出勤):亚洲5638美元(5638-5638),欧洲2660美元(641-5277),北美752美元(307-1303)。
  • 溃疡性结肠炎年缺勤成本(含假性出勤):亚洲4828美元(4828-4828),欧洲2394美元(651-5992),北美1443美元(85-2350)。

临床怎么用

  • 临床医生应了解生物制剂虽预期减少住院和手术,但住院费用并未下降,需关注药物成本控制。
  • 炎症性肠病对工作生产力有负面影响,临床评估时应考虑缺勤和假性出勤带来的社会成本。

局限性

  • 纳入研究的方法学差异很大,包括研究视角、估值方法和人群方面存在较大差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knowledge of the cost of illness of inflammatory bowel disease (IBD) is essential for health policy makers worldwide. AIM: To assess the cost of illness of IBD from the societal perspective taking into account time trends and geographical differences. METHODS: A systematic review of all population-based studies on cost of illness of IBD published in Embase, Medline, Web of Science and Google Scholar. Methodology of included studies was assessed and costs were adjusted to 2018 US dollars. RESULTS: Study methodologies differed considerably, with large differences in perspective, valuation method and population. For prevalent Crohn's disease (CD) cases in the last ten years annual healthcare costs were in Asia $4417 (range $1230-$31 161); Europe $12 439 ($7694-$15 807) and North America $17 495 ($14 454-$20 535). For ulcerative colitis (UC), these were $1606 ($309-$14 572), $7224 ($3228-$9779) and $13 559 ($13 559-$13 559). The main cost driver was medication, the cost of which increased considerably between 1985 and 2018, while outpatient and inpatient costs remained stable. IBD had a negative impact on work productivity. Annual costs of absenteeism for CD and UC were in Asia (with presenteeism) $5638 ($5638-$5638) and $4828 ($4828-$4828); Europe $2660 ($641-$5277) and $2394 ($651-$5992); North America $752 ($307-$1303) and $1443 ($85-$2350). CONCLUSION: IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van Linschoten RCA, Visser E, Niehot CD, et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol Ther. 2021. PMID: 34114667. doi:10.1111/apt.16445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。